PharmGen Science, Inc.
Financials
Valuation Metrics
PharmGen Science, Inc.'s Market Cap is ₩641B. At end of 2025 it was ₩941B. Ranked #1546 of 2,410 in KR market (top 64%), #645 of 779 on KOSPI (top 83%), #170 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 74%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 64.11B KRW | KR#1,546/2,410 Sec#170/231 |
| Revenue | 175.36B KRW | KR#1,102/2,410 Sec#66/231 |
| Net Income | -134.36B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 184.19B KRW | KR#1,370/2,410 Sec#101/231 |
| Net Assets | 140.04B KRW | KR#1,180/2,410 Sec#88/231 |
| Employees | 254 | KR#918/2,410 Sec#79/231 |
| Value | ||
| P/B | 0.46x | KR#771/2,410 Sec#29/231 |
| P/S | 0.37x | KR#764/2,410 Sec#23/231 |
| EV/EBITDA | 10.65x | KR#683/2,410 Sec#33/231 |
| FCF Yield | 6.02% | KR#821/2,410 Sec#41/231 |
| Profitability | ||
| ROE | -95.95% | KR#2,329/2,410 Sec#215/231 |
| ROA | -72.95% | KR#2,375/2,410 Sec#223/231 |
| Op. Margin | 2.39% | KR#1,327/2,410 Sec#96/231 |
| Revenue Growth | 0.42% | KR#1,497/2,410 Sec#149/231 |
| Earnings Growth | -3582.94% | KR#1,342/2,410 Sec#96/231 |
| Financial Health | ||
| Debt Ratio | 31.53% | KR#614/2,410 Sec#72/231 |
| Total Debt | 0 KRW | KR—/2,410 Sec—/231 |
| FCF | 3.86B KRW | KR#964/2,410 Sec#68/231 |
| Cash | 19.52B KRW | KR#1,267/2,410 Sec#94/231 |
| Current Ratio | 3.33x | KR#490/2,410 Sec#73/231 |
| Net Debt/EBITDA | -4.66x | KR#106/2,410 Sec#3/231 |
| Performance | ||
| 1Y Return | -29.86% | KR#1,495/2,410 Sec#119/231 |
| 1M Return | -0.70% | KR#591/2,410 Sec#63/231 |
| From 52W High | -36.90% | KR#661/2,410 Sec#42/231 |
| 1Y MDD | -38.41% | KR#509/2,410 Sec#34/231 |
| Trading | ||
| Volume | 21,591 shares | KR#1,633/2,410 Sec#167/231 |
| Trading Value | 60.5M KRW | KR#1,775/2,410 Sec#187/231 |
| Foreign Own. | 1.67% | KR#1,760/2,410 Sec#171/231 |
| Per Share | ||
| EPS | -5,931 KRW | KR—/2,410 Sec—/231 |
| BPS | 6,182 KRW | KR#1,355/2,410 Sec#94/231 |
Company Info
Established in 1966 as Sudo Pharmaceutical Industry, this company engages in digestive system therapeutics and health functional foods. With headquarters and production facilities in Hwaseong, Gyeonggi-do, it operates wholesale and national branches, a global R&D center, and a development division, focusing on selling professional and general pharmaceuticals and new drug development. In 2021, it established a biosimilar new drug division and recruited experts, and in 2022, announced its R&D Vision 2030, aiming to become a specialized company in digestive system new drug development.